Document text
Principal Investigator: Andre LaRochelle
Organization: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Fiscal Year: 2023
Award: $1,332,597
Funding agency: National Heart Lung and Blood Institute
Objective 1: Develop novel HSPC gene correction strategies
Because multiple causative mutations have been identified in FA, targeted introduction of a therapeutic open reading frame at the endogenous FANCA genetic locus is desirable to allow single-construct genetic correction regardless of the nature of downstream mutations. Due to faulty DNA repair mechanisms in FA cells, genome editing approaches that rely on CRISPR-Cas9-mediated DNA DSBs and subsequent repair are impractical in FA HSPCs. Accordingly, we are developing novel strategies that bypass the DNA damage response (DDR) for targeted integration. To this end, we have incorporated the programmability of CRISPR-Cas9 with the integration efficiency of DNA recombinase domains known to mediate enzymatic DNA ligation reactions without formation of de novo DNA free ends. Namely, we have constructed chimeric proteins with nuclease-deficient mutant of Cas9 (dCas9) molecularly fused to tandem domains of known eukaryotic transposases (e.g., Tn5, PiggyBac, and Sleeping Beauty) or HIV integrase to enable dCas9-directed, recombinase-mediated, DDR-independent integration of an FA donor substrate at the FANCA genetic locus. Testing of these approaches is underway.
Objective 2: Facilitate safe and efficient engraftment of gene-edited HSPCs
Pre-transplant conditioning with chemotherapy-free regimens. We hypothesized that cMPL might be a relevant antigen for an antibody-based targeted depletion of human HSPCs and provide the basis for a safer conditioning regimen prior to transplant. To investigate this possibility, we have produced a recombinant anti-cMPL bivalent (bi) single-chain fragment variable (scFV) fused with diphtheria toxin (DT) truncated at residue 390 (DT390-biscFV(cMPL)). This agent has enabled HSPC depletion in pre-clinical in vitro and non-human primate (NHP) models. Further optimization of dosage is underway in a knock-in mouse model harboring human TPO and cMPL gene sequences. We are also pursuing autologous transplantation of genetically barcoded HSPCs in NHPs conditioned with DT390-biscFV(cMPL). The safety and efficacy profiles is monitored long-term and detailed quantitative longitudinal follow-up is performed in barcoded animals to assess stability of contributions from engrafted HSPC clones.
Increase cell dose by ex vivo expansion of gene-edited HSPCs. To develop a clinically feasible platform for the expansion of genetically modified long-term repopulating adult HSPCs, we are building upon recent advances to develop a synthetic, cytokine-free expansion culture system that addresses the limited efficacy and batch-to-batch variability of current approaches. Three strategies are combined to further optimize culture conditions for HSPC expansion: 1) Promoting HSPC self-renewal. Key transcriptional regulators (e.g., HOXB4) have been identified as potential targets to enhance HSPC self-renewal in culture. Because constitutive expression of growth-promoting transcription factors (TFs) by viral transduction poses safety risks, we transiently express single or combined self-renewal regulators within target HSPCs in culture using lipid nanoparticle (LNP)-based transfer of TF mRNA; 2) Suppressing HSPC differentiation. We have recently identified 78c, a potent inhibitor of the CD38 differentiation marker, as a lead synthetic candidate for active suppression of HSPC differentiation in culture. 3) Mitigating endoplasmic reticulum (ER) stress. Recent studies have highlighted how increased proliferative demand triggers ER stress perturbations that collectively impair HSC function in ex vivo culture. To limit activation of ER stress pathways during expansion, we evaluate HSPC cultures under hypoxic conditions and supplemented with synthetic agonists of Hsf1 (e.g., 17-AAG) recently shown to limit ER stress by rebalancing proteostasis.
Increase cell fitness by overcoming innate immune responses. A growing body of experimental evidence suggests a pivotal role of host antiviral factors and nucleic acid sensors in limiting the efficacy of HSPC genetic manipulation. To characterize innate immune pathways triggered by reagents used for genetic engineering of HSPCs, we are conducting unbiased proteomic and single-cell transcriptomic screens on human HSC-enriched populations exposed to commonly used gene delivery systems, including vectors based on RV, LV, FV and AAV6, as well electroporation and lipid nanoparticle carriers of nucleic acid constituents (e.g., DNA and mRNA). These findings will inform novel approaches to overcome immune blocks to nucleic acid delivery and enhance gene correction efficiencies by promoting cellular survival and fitness.
Evaluate the impact of post-transplant G-CSF administration on gene-edited HSPCs. Granulocyte colony stimulating factor (G-CSF) is commonly used as adjunct treatment to hasten recovery from neutropenia following chemotherapy and autologous transplantation of hematopoietic stem and progenitor cells (HSPCs) for malignant disorders. However, the utility of G-CSF administration after ex vivo gene therapy procedures targeting human HSPCs has not been thoroughly evaluated. We provided evidence that post-transplant administration of G-CSF impedes engraftment of CRISPR-Cas9 gene edited human HSPCs in xenograft models. G-CSF acts by exacerbating the p53-mediated DNA damage response triggered by Cas9- mediated DNA DSBs. Transient p53 inhibition in culture attenuated the negative impact of G-CSF on gene edited HSPC function. In contrast, post-transplant administration of G-CSF did not impair the repopulating properties of unmanipulated human HSPCs or HSPCs genetically engineered by transduction with lentiviral vectors. The potential for post-transplant G-CSF administration to aggravate HSPC toxicity associated with CRISPR-Cas9 gene editing should be considered in the design of ex vivo autologous HSPC gene editing clinical trials. BioRxiv 2023: doi: 10.1101/2023.06.29.547089.
Objective 3: Develop in vivo gene therapy strategies
In vivo delivery of genetic payloads could circumvent the shortcomings of current ex vivo gene correction approaches and represent a distinct advance for gene therapy of Fanconi anemia. Among available in vivo delivery methods, LNPs are the most developed for clinical use. A 3-step preclinical study is underway to provide a comprehensive evaluation of the efficiency (Aim 1), safety (Aim 2) and therapeutic applicability (Aim 3) of novel LNP delivery systems.
Aim 1- In pilot experiments, we have identified and optimized a novel LNP formulation based on the ionizable dendrimer amino lipid 4A3-SC852, and shown efficacy for delivery of nucleic acid cargoes to purified human HSPCs in vitro. Building on our previous studies demonstrating cMPL as a relevant antigen to target HSPCs, optimized LNP formulations have been chemically conjugated to a recombinant anti-cMPL bivalent single-chain fragment variable (biscFV(cMPL)) to facilitate selective delivery of CRISPR reagents to HSPCs in a NHP model in vivo.
Aim 2- Specificity of LNP-mediated delivery of CRISPR reagents to HSPCs is imperative to limit off-target gene editing and systemic toxicity in vivo. To address this question, biodistribution of LNP formulations administered intravenously to NHPs are investigated using established in vivo tracking approaches. Briefly, biscFV(cMPL)-conjugated LNP formulations are encapsulated with the sodium/iodide symporter (NIS) mRNA, infused to the animals, and tracked by whole-body PET/CT scan imaging at select timepoints following intravenous injection of an 18F-tetrafluoroborate radiotracer.
Aim 3- Integration of an FA donor substrate at the endogenous locus within HSPCs will be pursued in NHPs by cMPL-conjugated LNP delivery of a dCas9-directed, recombinase-mediated, DDR-independent genome editing system.
Terms: <21+ years old><Active Follow-up><Address><Adult><Adult Human><Agonist><Allergy><Animals><Antibodies><Antigens><Antioncogene Protein p53><Apoptosis><Apoptosis Pathway><Attenuated><Autograft><Autologous><Autologous Transplantation><Autotransplant><Bar Codes><Basal Transcription Factor><Basal transcription factor genes><Biodistribution><Blood Diseases><Blood Precursor Cell><Bone marrow failure><Bypass><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cell Differentiation><Cell Differentiation process><Cells><Cellular Tumor Antigen P53><Chimera Protein><Chimeric Proteins><Clinical><Clinical Trials><Clone Cells><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Co-Transporters><Colony Stimulating Factor 3><Congenital Pancytopenia><Corynebacterium Diphtheriae Toxin><DNA><DNA Damage><DNA Damage Repair><DNA Double Strand Break><DNA Injury><DNA Ligation><DNA Repair><DNA Repair Deficiency><DNA Repair Disorder><DNA Therapy><Dendrimers><Dendritic Compounds><Dendrons><Deoxyribonucleic Acid><Differentation Markers><Differentiation Antigens><Differentiation Markers><Diphtheria Toxin><Disease><Disorder><Dose><Double Strand Break Repair><ER stress><Electroporation><Encapsulated><Engineering><Engraftment><Eosinophil-Mast Cell Growth-Factor><Erythrocyte Burst-Promoting Factor><Evaluation><Event><Exposure to><FANCA><FANCA Protein><Fanconi Anemia><Fanconi Anemia Complementation Group A Protein><Fanconi Anemia Group A Complementing Protein><Fanconi Anemia Group A Protein><Fanconi Panmyelopathy><Fanconi dysplasia><Fanconi's Anemia><Formulation><Fusion Protein><Gammaretrovirus><Gene Delivery><Gene Modified><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Genetic Intervention><Genetic Transcription><Genetic defect><Genome><Granulocyte Colony-Stimulating Factor><Growth><HIV Integrase><HIV Integration Protein><Hematologic Diseases><Hematological Disease><Hematological Disorder><Hematopoietic Cytokine><Hematopoietic Progenitor Cells><Hematopoietic stem cells><Hereditary><Human><Hypersensitivity><Hypoxia><Hypoxic><IFN><IL-3><IL-3 Gene><IL3><IL3 Gene><IL3 Protein><Image><Immune><Immunes><Impairment><In Situ><In Vitro><Inflammation Mediators><Inflammatory><Inherited><Innate Immune Response><Interferons><Iodides><KI mice><Knock-in Mouse><Lead><Lentiviral Vector><Lentivirinae><Lentivirus><Lentivirus Vector><Lipids><Malignant Cell><Mammalian Type C Retroviruses><Marker Antigens><Marrow><Mast-Cell Colony-Stimulating Factor><Mediating><Messenger RNA><Methods><Modeling><Modern Man><Molecular><Monitor><Morbidity><Morbidity - disease rate><Mutation><Na element><Nature><Neutropenia><Nucleic Acids><ORFs><Oncoprotein p53><Open Reading Frames><Outcome><Oxygen Deficiency><P-CSF><P-Cell Stimulating Factor><P53><PET/CT><PET/CT scan><Pathway interactions><Patients><Pb element><Phosphoprotein P53><Phosphoprotein pp53><Pluripoietin><Population><Primary Erythroid Hypoplasia><Procedures><Programmed Cell Death><Property><Protein Coding Region><Protein TP53><Proteomics><Protocol><Protocols documentation><RNA Expression><Radiation><Reaction><Reagent><Recombinant DNA Technology><Recombinants><Recovery><Regimen><Reserve Cell><Residual><Residual state><Retroviral Vector><Retrovirus Vector><Risk><Role><Safety><Sleeping Beauty><Sodium><Specificity><System><TP53><TP53 gene><TRP53><Testing><Therapeutic><Tissue Growth><Toxic effect><Toxicities><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transplantation><Transplantation Conditioning><Transposase><Tumor Protein p53><Tumor Protein p53 Gene><Unscheduled DNA Synthesis><Viral><Xenograft Model><active followup><adulthood><attenuate><attenuates><autologous graft><autotransplantation><barcode><blood disorder><blood stem cell><bone marrow failure syndrome><cancer cell><causal allele><causal gene><causal mutation><causal variant><causative mutation><causative variant><chemical conjugate><chemotherapeutic agent><chemotherapy><conditioning><congenital aplastic anemia><constitutive expression><constitutive gene expression><cytokine><cytotoxic><design><designing><dosage><electroporative delivery><endoplasmic reticulum stress><experiment><experimental research><experimental study><experiments><fitness><follow up><follow-up><followed up><followup><gene corrected><gene correction><gene delivery system><gene electrotransfer><gene locus><gene manipulation><gene modification><gene repair therapy><gene therapy><gene transfer vector><gene-based therapy><genetic approach><genetic locus><genetic manipulation><genetic payload><genetic strategy><genetic therapy><genetically engineered><genetically engineered cells><genetically manipulate><genetically modified cells><genetically perturb><genome editing><genome mutation><genomic editing><genomic location><genomic locus><genomic therapy><granulocyte colony stimulating factor><heavy metal Pb><heavy metal lead><hematopoietic engraftment><hematopoietic progenitor><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><imaging><immunogen><in vivo><in vivo Model><inflammatory mediator><inhibitor><innate immune pathways><intravenous administration><intravenous injection><knockin mice><lipid based nanoparticle><lipid nanoparticle><mRNA><mortality><mouse model><murine model><mutant><nano particle delivery><nanoparticle delivered><nanoparticle delivery><new approaches><non-human primate><nonhuman primate><novel><novel approaches><novel strategies><novel strategy><nuclease><nucleic acid delivery><ontogeny><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><positron emission computed tomography><post-transplant><post-transplantation><posttransplant><posttransplantation><pre-clinical><pre-clinical study><precise genome editing><preclinical><preclinical study><progenitor cell function><programs><protein homeostasis><protein p53><proteostasis><radiolabel><radiolabels><radiotracer><recombinase><repair><repaired><response><risk minimization><self-renew><self-renewal><sensor><social role><stem cell function><symporter><systemic toxicity><transcription factor><transcriptomics><transplant><vector><xenograft transplant model><xenotransplant model><γ-retrovirus>